Cargando…

Analytical Method Development and Validation for the Simultaneous Estimation of Abacavir and Lamivudine by Reversed-phase High-performance Liquid Chromatography in Bulk and Tablet Dosage Forms

OBJECTIVE: A simple rapid, accurate, precise, and reproducible validated reverse phase high performance liquid chromatography (HPLC) method was developed for the determination of Abacavir (ABAC) and Lamivudine (LAMI) in bulk and tablet dosage forms. METHODS: The quantification was carried out using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raees Ahmad, Sufiyan Ahmad, Patil, Lalit, Mohammed Usman, Mohammed Rageeb, Imran, Mohammad, Akhtar, Rashid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855381/ https://www.ncbi.nlm.nih.gov/pubmed/29568194 http://dx.doi.org/10.4103/pr.pr_96_17

Ejemplares similares

Abacavir/lamivudine combination in the treatment of HIV: a review
por: Sivasubramanian, Geetha, et al.
Publicado: (2010)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children
por: Gitta, PK, et al.
Publicado: (2010)

Similar Durability of Two Single Tablet Regimens, Dolutegravir/Abacavir/Lamivudine and Elvitegravir/Cobicistat/Tenofovir/Emtricitabine: Single Center Experience
por: Chin, Bum Sik, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants
por: Singh, Rajendra P., et al.
Publicado: (2021)

Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults
por: Singh, Rajendra P., et al.
Publicado: (2018)

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single‐tablet regimen in a multicentre cohort in Spain
por: Suárez‐García, Inés, et al.
Publicado: (2021)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
por: Cruciani, Mario, et al.
Publicado: (2015)

Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
por: Olalla, Julián, et al.
Publicado: (2018)

Abacavir/dolutegravir/lamivudine: Delayed hepatotoxicity and drug-induced liver injury: case report
Publicado: (2021)

A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1
por: Shin, Sang-Kyu, et al.
Publicado: (2023)

Development and validation of a HPTLC method for Estimation of Duloxetine Hydrochloride in Bulk Drug and in Tablet Dosage Form
por: Dhaneshwar, Suneela S., et al.
Publicado: (2008)

Correction to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
por: Olalla, Julián, et al.
Publicado: (2023)

RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form
por: Bhavsar, Dhara S., et al.
Publicado: (2012)

Spectrophotometeric Determination of Cefuroxime Axetil from bulk and in its tablet dosage form
por: Shinde, M. V., et al.
Publicado: (2008)

Safety and Effectiveness Analysis of Kivexa(®) (lamivudine/abacavir sulfate) in Human Immunodeficiency Virus Infected Korean Patients
por: Ann, Heawon, et al.
Publicado: (2019)

Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
por: Christensen, Erin S., et al.
Publicado: (2017)

Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2012)

Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Martin, Allison, et al.
Publicado: (2011)

Drug-Drug Interaction of Ergotamine with a Combination of Darunavir, Abacavir, and Lamivudine Causing a Fatal Vasospastic Ischemia
por: Petit, Elisabeth, et al.
Publicado: (2018)

Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
por: Alzate Angel, Juan Carlos, et al.
Publicado: (2017)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data
por: Rodriguez, Allan E, et al.
Publicado: (2010)

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
por: Wolf, E, et al.
Publicado: (2010)

Hip Structural Parameters over 96 Weeks in HIV-Infected Adults Switching Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2014)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: M. Llibre, Josep, et al.
Publicado: (2016)

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study
por: Llibre, Josep M., et al.
Publicado: (2016)

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load
por: Galizzi, Nadia, et al.
Publicado: (2018)

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
por: Troya, Jesús, et al.
Publicado: (2018)

A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes
por: Ferrer, Pedro E, et al.
Publicado: (2017)

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
por: Squires, Kathleen E, et al.
Publicado: (2017)

Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
por: Bunupuradah, Torsak, et al.
Publicado: (2015)

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019)

Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient
por: Saad, Muhammad, et al.
Publicado: (2019)

Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study
por: Bekker, Adrie, et al.
Publicado: (2022)

Development and Validation of a RP-HPLC Method for Estimation of Montelukast Sodium in Bulk and in Tablet Dosage Form
por: Singh, R. M., et al.
Publicado: (2010)

Azeotropic mixture used for development and validation of Lornoxicam in bulk and its tablet dosage form by spectrophotometric method
por: Prajapati, Prajesh, et al.
Publicado: (2012)

Spectrophotometric Methods for the Determination of Cefprozil in Bulk and Dosage Form
por: Gadkariem, Elrasheed A., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lct2rjsf6vrvvsm4jqu05s55lg